1 Sep 2022 07:00
1 September 2022
Diurnal Group plc
("Diurnal" or the "Company")
Postponement of R&D Day and Notice of Results
Diurnal Group plc (AIM:DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that following a recommended cash acquisition for Diurnal by Neurocrine Biosciences, announced on 30 August 2022, the Company is postponing its R&D Day scheduled to be held on 7 September 2022.
In addition, the Company expects to report its interim results for the twelve-month period ended 30 June 2022 on 14 September 2022.
For further information, please visit www.diurnal.co.uk or contact: | ||
Diurnal Group plc | +44 (0)20 3727 1000 | |
Richard Bungay, Interim Chief Executive Officer |
| |
| ||
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker) | +44 (0)20 7886 2500 | |
Corporate Finance: Freddy Crossley, Emma Earl |
| |
Corporate Broking: Rupert Dearden
|
| |
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | +44 (0) 20 7710 7600 |
|
Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown |
|
|
Corporate Broking: Nick Adams, Nick Harland |
|
|
| ||
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 | |
Simon Conway | ||
Victoria Foster Mitchell | ||
Alex Davis | ||
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
DNL.L (DNL)